Research programme: engineered cell therapy - Sana Biotechnology
Latest Information Update: 21 Jun 2023
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; Cardiovascular therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Cardiovascular disorders
Most Recent Events
- 16 Jun 2023 Pharmacokinetics data from preclinical trial in Cancer released by Sana Biotechnology
- 12 Apr 2023 Pharmacodynamics data from preclinical studies in Type 1 diabetes mellitus released by Sana Biotechnology
- 10 Dec 2022 Pharmacodynamics data from a preclinical studies in Cancer presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)